Animal study · mice

Retatrutide: 24.1% weight loss in MC4R-deficient mice over 21 days

Checked against the paper Animal studyPublished by PepVault

The takeaway

In mice missing the MC4R pathway, retatrutide still produced sizable weight loss, between semaglutide and tirzepatide in this study, with lean mass lost alongside fat.

Kind
Animal study
Studied in
Mice
Published
2026
Journal
Int J Obes (Lond)

What they tested

The team tested whether semaglutide, tirzepatide and retatrutide still cause weight loss in mice lacking MC4R, a brain receptor that helps control eating and body weight, and how the three compare.

How the study was done

An animal study in MC4R knockout mice (mice bred without a working MC4R gene) given semaglutide, tirzepatide or retatrutide for 21 days, with the three drugs compared to each other.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking retatrutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

In MC4R knockout mice, body weight fell by 24.1 ± 5.8% with retatrutide, 19.7 ± 4.1% with semaglutide and 31.6 ± 7.6% with tirzepatide. Echo-MRI scans showed all three drugs significantly lowered both fat mass and lean mass. All three improved plasma insulin, HOMA-IR (a measure of insulin resistance), cholesterol and the liver damage markers AST and ALT, and reduced liver enlargement. They lowered genes tied to fatty acid synthesis but had no significant effect on inflammation-related genes. They also reduced energy expenditure, and only tirzepatide significantly lowered the respiratory quotient.

What it doesn’t show

This was a 21-day study in mice, so it isn't a human result and doesn't show what happens in people with MC4R or POMC pathway defects. Lean mass dropped along with fat mass in these mice.

The paper

Hitaka et al. Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison. Int J Obes (Lond). 2026.

The compounds

More studies on Retatrutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking retatrutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo